CoLucid Pharmaceuticals Announces Pricing of Initial Public Offering
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
CoLucid Pharmaceuticals (CLCD) IPO Opens Down 15%
May 6, 2015 11:56 AM EDTToday's IPO for CoLucid Pharmaceuticals, Inc. (Nasdaq: CLCD) opened for trading at $8.50 after pricing 5,500,000 shares of common stock at a public offering price of $10.00 per share.
Piper Jaffray & Co. and Stifel are acting as joint book-running managers for the offering.... More
